Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.

[1]  Samuel Hellman,et al.  Important advances in oncology , 1991 .

[2]  F. Labrie,et al.  Treatment of hirsutism with the pure antiandrogen flutamide. , 1990, Journal of the American Academy of Dermatology.

[3]  J. Simard,et al.  Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate , 1990, Molecular and Cellular Endocrinology.

[4]  M. Keating,et al.  Long-term experience with flutamide in patients with prostatic carcinoma. , 1989, Urology.

[5]  F. Labrie,et al.  Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer. , 1989, Journal of steroid biochemistry.

[6]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[7]  B. Stricker,et al.  Flutamide and hepatitis. , 1989, Annals of internal medicine.

[8]  F. Labrie,et al.  Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. , 1988, Journal of steroid biochemistry.

[9]  M MurieCarrillodeAlbornoz,et al.  [Toxic and drug-induced hepatitis]. , 1988 .

[10]  F. Labrie,et al.  Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. , 1988, Journal of steroid biochemistry.

[11]  F. Rasmussen,et al.  Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study. , 1988, British journal of urology.

[12]  C. Labrie,et al.  Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. , 1987, Journal of steroid biochemistry.

[13]  R. Macsween.  Pathology of the Liver , 1981 .

[14]  H. Zimmerman,et al.  Drug-Induced Cholestasis , 1987, Medical toxicology.

[15]  P. Poyet,et al.  Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate , 1985, Molecular and Cellular Endocrinology.

[16]  R. Gordon,et al.  The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. , 1975, The Journal of urology.

[17]  B. Katchen,et al.  Disposition of a New, Nonsteroid, Antiandrogen, α,α,α-Trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in Men Following a single Oral 200 mg Dose , 1975 .

[18]  R. Neri,et al.  Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia. , 1972, Investigative urology.

[19]  R. Neri,et al.  Biological studies on an anti-androgen (SH 714). , 1967, European journal of pharmacology.

[20]  J. Johansson,et al.  Flutamide — An antiandrogen inhibiting prostatic cancer and prostatic secretion with retention of potency , 1988, Medical oncology and tumor pharmacotherapy.

[21]  M. Giasson,et al.  Plasma levels of hydroxy‐flutamide in patients with prostatic cancer receiving the combined hormonal therapy: An LHRH agonist and flutamide , 1988, The Prostate.

[22]  M. E. El Etreby,et al.  Effect of cyproterone acetate in comparison to flutamide and megestrol acetate on the ventral prostate, seminal vesicle, and adrenal glands of adult male rats , 1988, The Prostate.

[23]  J. Johansson,et al.  Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate. , 1987, Urology.

[24]  F. Labrie,et al.  Complete androgen blockade for the treatment of prostate cancer. , 1985, Important advances in oncology.

[25]  W. Whitmore,et al.  Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy , 1984, Cancer.

[26]  Leon Schiff,et al.  Diseases of the liver , 1975 .

[27]  H. Eastwood.  Causes of Jaundice in the Elderly , 1971 .